NAMS
NewAmsterdam Pharma Company N.V.
There isn't enough reported data to score NAMS yet.
NAMS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
NAMS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NAMS PE Valuation
NAMS has no meaningful PE right now: it lost money over the past year.
NAMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NAMS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NAMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.68 | +$0.33 |
| Q2 2026 | -$2.15 | -$0.57 |
| Q1 2026 | -$1.78 | +$0.06 |
| Q4 2025 | -$1.72 | +$0.84 |
| Q3 2025 | -$2.01 | +$0.16 |
| Q2 2025 | -$1.58 | +$0.97 |
| Q1 2025 | -$1.84 | +$0.73 |
| Q4 2024 | -$2.56 | -$0.58 |
NAMS is still losing money, but far less than before: $1.68 per share over the past year, against $3.66 at its worst in late 2023.
NAMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.2M | +5407% |
| Q2 2026 | $3.7M | -81% |
| Q1 2026 | $3M | +2.1% |
| Q4 2025 | $32K | -100% |
| Q3 2025 | $348K | -99% |
| Q2 2025 | $19.1M | +740% |
| Q1 2025 | $3M | +113% |
| Q4 2024 | $12.8M | +1491% |
NAMS's revenue is recovering but still below its 2022 peak: $19M last quarter, up 5407% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -231% | +15615 points |
| Q2 2026 | -1753% | -1567 points |
| Q1 2026 | -1922% | +393 points |
| Q4 2025 | -206188% | -205849 points |
| Q3 2025 | -15846% | -15760 points |
| Q2 2025 | -186% | +2121 points |
| Q1 2025 | -2314% | +1646 points |
| Q4 2024 | -338% | +6022 points |
NAMS's operating margin was −231% last quarter, up 15615 points from the same quarter a year ago.
NAMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40M | -$7.1M |
| Q2 2026 | -$39.3M | -$1.5M |
| Q1 2026 | -$30.6M | +$5.8M |
| Q4 2025 | -$41M | -$3.5M |
| Q3 2025 | -$32.8M | -$20.2M |
| Q2 2025 | -$37.8M | +$16.4M |
| Q1 2025 | -$36.5M | +$18.5M |
| Q4 2024 | -$37.5M | -$4.4M |
NAMS has burned cash in almost every quarter: −$151M over the past year, against −$145M the year before.
NAMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +766K shares |
| 1 year | +4.3% | +5.1M shares |
| 3 years | +51% | +41.7M shares |
| 5 years | +44% | +38M shares |
NAMS has 124M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
NAMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -55.9x | Net Cash |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -16.5x | Net Cash |
NAMS has more cash than debt.
NAMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 10.1 | Oversold |
NAMS's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
NAMS PE vs Healthcare Sector
| Metric | NAMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NAMS has no meaningful PE right now: it lost money over the past year.
NAMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.7 | 3.7% below |
| 20 week MA | $25.2 | 21% below |
| 50 week MA | $30.0 | 33% below |
| 100 week MA | $27.3 | 27% below |
| 200 week MA | $21.4 | 6.6% below |
NAMS is in a downtrend: it's below all five of its weekly moving averages, and 6.6% below its 200-week average.
NAMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.6 | $9.74 | -8.5% |
| 2022 | $9.74 | $11.3 | +16% |
| 2023 | $11.3 | $11.2 | -1.2% |
| 2024 | $11.2 | $25.9 | +132% |
| 2025 | $25.9 | $35.3 | +36% |
| 2026 YTD | $35.3 | $20.0 | -43% |
NAMS is down 43% so far in 2026, after finishing higher in three of the previous five years.